| __timestamp | Iovance Biotherapeutics, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 19928000 |
| Thursday, January 1, 2015 | 12390000 | 30842000 |
| Friday, January 1, 2016 | 25602000 | 46527000 |
| Sunday, January 1, 2017 | 21262000 | 34451000 |
| Monday, January 1, 2018 | 28430000 | 34409000 |
| Tuesday, January 1, 2019 | 40849000 | 34417000 |
| Wednesday, January 1, 2020 | 60210000 | 145290000 |
| Friday, January 1, 2021 | 83664000 | 298358000 |
| Saturday, January 1, 2022 | 104097000 | 488691000 |
| Sunday, January 1, 2023 | 106916000 | 468946000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Iovance Biotherapeutics, Inc. and Novavax, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. Iovance's expenses have grown steadily, increasing by over 1,000% from 2014 to 2023, reflecting their strategic investments in research and development. Meanwhile, Novavax experienced a dramatic surge, with expenses skyrocketing by over 2,200% during the same period, peaking in 2022. This spike aligns with their aggressive push in vaccine development, particularly during the COVID-19 pandemic. The data highlights the dynamic nature of the biotech industry, where financial strategies can significantly impact a company's trajectory. As these companies continue to innovate, their SG&A expenses will remain a key indicator of their operational focus and market strategy.
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared